CPC
CTMX icon

Congress Park Capital’s CytomX Therapeutics CTMX Stock Holding History

Congress Park Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-400
Closed -$1K – 89
2018
Q4 		$1K Buy
+400
New +$5.93K ﹤0.01% 84

Other funds holding CTMX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
AGP
Aspire Growth Partners Miromar Lakes, Florida $172M AUM 33.61% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Congress Park Capital's CTMX Position: Q2 2026 in Review

Congress Park Capital held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 49,171 shares worth $184K. The position accounts for 0.05% of the portfolio, ranked #134.

Congress Park Capital first reported a position in CTMX in Q4 2017 and has held it in 28 quarters since. The position peaked at $3.06M in Q1 2018. 23 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Congress Park Capital held 49,171 shares of CytomX Therapeutics worth $184K as of Q2 2026.
  • Congress Park Capital left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up 0.05% of Congress Park Capital's portfolio in Q2 2026, its #134 holding.
  • Congress Park Capital first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 28 quarters since.
  • Congress Park Capital's CytomX Therapeutics position peaked at $3.06M in Q1 2018.
  • 23 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.